NeurogesX Inc. reported the pain patch NGX-4010 met primary and secondary endpoints in a third Phase III trial, and the second in patients with postherpetic neuralgia. (BioWorld Today)

Acambis plc has won FDA approval for its smallpox vaccine ACAM 2000, the first new biodefense vaccine to be licensed since the U.S. government launched Project Bioshield in 2001. (BioWorld International)